Ziylo’s technology platform could accelerate the development of a groundbreaking treatment for diabetes patients
A new company, Carbometrics, has been set up to develop novel diagnostics and glucose monitoring
BRISTOL, UK 17 August 2018 – Unit DX, the scientific incubator in Bristol announces that its member Ziylo has been acquired by global healthcare company Novo Nordisk A/S in an agreement that could exceed US$800 million. Ziylo’s innovative technology platform offers the potential to develop glucose responsive insulins, a ground-breaking treatment for diabetes patients worldwide.
Ziylo was co-founded by Dr Harry Destecroix, CEO while finishing his PhD in the Anthony Davis Lab at the University of Bristol. He is also the co-founder of Unit DX, along with Tom Smart, CFO and Keith MacDonald, Chairman.